J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
CNBC Stocks· Oct 13, 2026 · 5:44 PM
J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 8 hours ago
Tesla, Samsung oppose new US tariffs on Vietnam as probe deadline nears
Investing.com
stocksabout 8 hours ago
China’s robot makers have mastered the moves. Now comes the race for brains
Investing.com
stocksabout 8 hours ago
SK Hynix trapped in cloud resistance bear flag: Live levels
Investing.com